Epigenetic inactivation of the putative DNA/RNA helicase SLFN11 in human cancer confers resistance to platinum drugs

Oncotarget

Volumn 7, Issue 3, 2016, Pages 3084-3097

  Nogales, Vanesa ^a   Reinhold, William C ^b   Varma, Sudhir ^b   Martinez Cardus, Anna ^a   Moutinho, Catia ^a   Moran, Sebastian ^a   Heyn, Holger ^a   Sebio, Ana ^c   Barnadas, Agusti ^c   Pommier, Yves ^b   Esteller, Manel ^a,d,e  

^a BELLVITGE BIOMEDICAL RESEARCH INSTITUTE IDIBELL   (Spain)

^b NATIONAL CANCER INSTITUTE   (United States)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF BARCELONA   (Spain)

^e INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

Chemoresistance; CpG island methylation; DNA damaging agents; Epigenetics; SLFN11

Indexed keywords

BIOLOGICAL MARKER; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; HELICASE; PACLITAXEL; TAXANE DERIVATIVE; ANTINEOPLASTIC AGENT; DEAD BOX PROTEIN; DHX9 PROTEIN, HUMAN; DNA; NUCLEAR PROTEIN; SLFN11 PROTEIN, HUMAN; SMALL INTERFERING RNA; TUMOR PROTEIN;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CELL VIABILITY; CPG ISLAND; DNA METHYLATION; ENZYME INACTIVATION; EPIGENETICS; FEMALE; GENE INTERACTION; GENE SILENCING; HUMAN; IC50; IMMUNOPRECIPITATION; IN VITRO STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; OVARY CANCER; PROGRESSION FREE SURVIVAL; SLFN11 GENE; CARCINOMA, NON-SMALL-CELL LUNG; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HCT 116 CELL LINE; HEK293 CELL LINE; LUNG NEOPLASMS; MCF-7 CELL LINE; METABOLISM; OVARIAN NEOPLASMS; RNA INTERFERENCE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; CPG ISLANDS; DEAD-BOX RNA HELICASES; DNA; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HCT116 CELLS; HEK293 CELLS; HUMANS; LUNG NEOPLASMS; MALE; MCF-7 CELLS; MIDDLE AGED; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84962235485     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6413     Document Type: Article

References (32)

1. Puisset F, Schmitt A, Chatelut E. Standardization of chemotherapy and individual dosing of platinum compounds. Anticancer Research. 2014; 34: 465-470.
2. Boulikas T, Vougiouka M. Recent clinical trials using cisplatin, carboplatin and their combination chemotherapy drugs (review). Oncology Reports. 2004; 11: 559-595.
3. Haugnes HS, Bosl GJ, Boer H, Gietema JA, Brydøy M, Oldenburg J, Dahl AA, Bremnes RM, Fosså SD. Long-term and late effects of germ cell testicular cancer treatment and implications for follow-up. Journal of Clinical Oncology. 2012; 30: 3752-3763.
4. McKeage MJ. Comparative adverse effect profiles of platinum drugs. Drug Safety. 1995; 13: 228-244.
5. Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012; 31: 1869-1883.
6. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer (Review). Oncology Reports. 2004; 12: 955-965.
7. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clinical Cancer Research. 2008; 14: 1291-1295.
8. Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, et al. Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. Journal of Clinical Oncology. 2010; 28: 1145-1153.
9. Stefansson OA, Villanueva A, Vidal A, Martí L, Esteller M. BRCA1 epigenetic inactivation predicts sensitivity to platinum-based chemotherapy in breast and ovarian cancer. Epigenetics. 2012; 7: 1225-1229.
10. Topp MD, Hartley L, Cook M, Heong V, Boehm E, McShane L, Pyman J, McNally O, Ananda S, Harrell M, Etemadmoghadam D, Galletta L, Alsop K, et al. Molecular correlates of platinum response in human high-grade serous ovarian cancer patient-derived xenografts. Molecular oncology. 2014; 8: 656-668.
11. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Research. 2001; 61: 3225-3229.
12. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nature Reviews. 2012; 13: 679-692.
13. Moutinho C, Martinez-Cardús A, Santos C, Navarro-Pérez V, Martínez-Balibrea E, Musulen E, Carmona FJ, Sartore-Bianchi A, Cassingena A, Siena S, Elez E, Tabernero J, Salazar R, Abad A, Esteller M. Epigenetic inactivation of the BRCA1 interactor SRBC and resistance to oxaliplatin in colorectal cancer. Journal of the National Cancer Institute. 2014; 106: djt322.
14. Ellinger J, Haan K, Heukamp LC, Kahl P, Büttner R, Müller SC, von Ruecker A, Bastian PJ. CpG island hypermethylation in cell-free serum DNA identifies patients with localized prostate cancer. Prostate. 2008; 68: 42-49.
15. Sandoval, Heyn H, Moran S, Serra-Musach J, Pujana MA, Bibikova M, Esteller M. Validation of a DNA methylation microarray for 450, 000 CpG sites in the human genome. Epigenetics. 2011; 6: 692-702.
16. Scherf U, Ross DT, Waltham M, Smith LH, Lee JK, Tanabe L, Kohn KW, Reinhold WC, Myers TG, Andrews DT, Scudiero DA, Eisen MB, Sausville EA, et al. A gene expression database for the molecular pharmacology of cancer. Nature genetics. 2000; 24: 236-244.
17. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nature Reviews Cancer. 2006; 6: 813-823.
18. Zoppoli G, Regairaz M, Leo E, Reinhold WC, Varma S, Ballestrero A, Doroshow JH, Pommier Y. Putative DNA/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents. Proceedings of the National Academy of Sciences. 2012; 109: 15030-15035.
19. Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002; 416: 552-556.
20. Li M, Kao E, Gao X, Sandig H, Limmer K, Pavon-Eternod M, Jones TE, Landry S, Pan T, Weitzman MD, David M. Codon-usage-based inhibition of HIV protein synthesis by human schlafen 11. Nature. 2012; 491: 125-128.
21. Schlegel BP, Starita LM, Parvin JD. Overexpression of a protein fragment of RNA helicase A causes inhibition of endogenous BRCA1 function and defects in ploidy and cytokinesis in mammary epithelial cells. Oncogene. 2013; 22: 983-991.
22. Jain A, Bacolla A, Del Mundo IM, Zhao J, Wang G, Vasquez KM. DHX9 helicase is involved in preventing genomic instability induced by alternatively structured DNA in human cells. Nucleic acids research. 2013; 41: 10345-10357.
23. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nature genetics. 1998; 19: 254-256.
24. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehár J, Kryukov GV, Sonkin D, Reddy A, Liu M, Murray L, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012; 483: 603-607.
25. Tian L, Song S, Liu X, Wang Y, Xu X, Hu Y, Xu J. Schlafen-11 sensitizes colorectal carcinoma cells to irinotecan. Anticancer Drugs. 2014; 25: 1175-1181.
26. Mavrommatis E, Fish EN, Platanias LC. The schlafen family of proteins and their regulation by interferons. Journal of Interferon & Cytokine Research. 2013; 33: 206-210.
27. Brosh RM Jr. DNA helicases involved in DNA repair and their roles in cancer. Nature Reviews Cancer. 2013; 13: 542-558.
28. Maréchal A, Li JM, Ji XY, Wu CS, Yazinski SA, Nquyen HD, Liu S, Jiménez AE, Jin J, Zou L. PRP19 transforms into a sensor of RPA-ssDNA after DNA damage and drives ATR activation a ubiquitin-mediated circuitry. Molecular Cell. 2014; 53: 235-246.
29. Woods NT, Mesquita RD, Sweet M, Carvalho MA, Li X, Liu Y, Nquyen H, Thomas CE, Iversen ES Jr, Marsillac S, Karchin R, Monteiro AN. Charting the landscape of tandem BRCT domain-mediated protein interactions. Science signaling. 2012; 5: rs6.
30. Fuller-Pace FV. DExD/H box RNA helicases: multifunctional proteins with important roles in transcriptional regulation. Nucleic acids research. 2006; 34: 4206-4215.
31. Jarmoskaite I, Russell R. RNA helicase proteins as chaperones and remodelers. Annual review of biochemistry. 2014; 83: 697-725.
32. Anderson SF, Schlegel BP, Nakajima T, Wolpin ES, Parvin JD. BRCA1 protein is linked to the RNA polymerase II holoenzyme complex via RNA helicase A. Nature genetics. 1998; 19: 254-256.